1. McManus KA, Powers S, Killelea A, Tello-Trillo S, Rogawski McQuade E. Regional disparities in qualified health plans’ prior authorization requirements for HIV pre-exposure prophylaxis in the United States. JAMA Netw Open. 2020;3(6):e207445
  2. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update: clinical providers’ supplement. Published March 2018. Accessed March 22, 2021.
  3. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update: a clinical practice guideline. March 2018. Accessed March 22, 2021.
  4. Med-IQ-SMA Current Practices Questionnaire survey. February 2021.
  5. Lopez MI, Dong BJ. Implementing PrEP in the pharmacy. Pharmacy Today. April 2020:39-53. 
  6. Truvada. Prescribing Information. Gilead Sciences, Inc.; 2020.
  7. Descovy. Prescribing Information. Gilead Sciences, Inc.; 2021.
  8. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
  9. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
  10. Thigpen MC, Kebaabetswe PM, Paxton LA, et al; TDF2 Study Group. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
  11. Choopanya K, Martin M, Suntharasamai P, et al; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.
  12. Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017;171(11):1063-1071.
  13. Grant RM, Anderson PL, McMahan V, et al; iPrEx study team. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
  14. Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial. Lancet. 2020;396(10246):239-254.
  15. Long-Acting HIV Prevention Tools. Accessed March 22, 2021.
  16. Healio News. FDA designates long-acting PrEP a breakthrough therapy. Published November 17, 2020. Accessed March 22, 2021.
  17. National Institutes of Health. Long-acting injectable form of HIV prevention outperforms daily pill in NIH study. Published July 7, 2020. Accessed March 22, 2021.
  18. World Health Organization. Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women. Published November 9, 2020. Accessed March 22, 2021.
  19. Koss CA, Hosek SG, Bacchetti P, et al. Comparison of measures of adherence to human immunodeficiency virus preexposure prophylaxis among adolescent and young men who have sex with men in the United States. Clin Infect Dis. 2018;66(2):213-219.
  20. Hosek S, Siberry G, Bell M, et al. Project PrEPare (ATN082): the acceptability and feasibility of an HIV pre-exposure prophylaxis (PrEP) trial with young men who have sex with men (YMSM). J Acquir Immune Defic Syndr. 2013;62(4).
  21. Brawley S, Dinger J, Nguyen C, Anderson J. Impact of COVID-19 related shelter-in-place orders on PrEP access, usage and HIV risk behaviors in the United States. AIDS 2020: 23rd International AIDS Conference Virtual. July 6-10, 2020. Abstract OADLB0101. Accessed March 22, 2021.
  22. Budak JZ, Scott JD, Dhanireddy S, Wood BR. The impact of COVID-19 on HIV care provided via telemedicine—past, present, and future. Curr HIV/AIDS Rep. 2021 Feb 22;1-7.
  23. Centers of Disease Control and Prevention. PrEP During COVID-19. Dear Colleagues Letters. May 15, 2020. Accessed March 22, 2021.
  24. Cottrell ML, Yang KH, Prince HMA, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214(1):55-64.
  25. Conniff J, Evensen A. Preexposure prophylaxis (PrEP) for HIV prevention: the primary care perspective. J Am Board Fam Med. 2016;29(1):143-151.
  26. NYC Health. A user’s guide to PrEP. Accessed March 25, 2021.
  27. Glidden DV, Amico KR, Liu AY, et al. Symptoms, side effects and adherence in the iPrEx open-label extension. Clin Infect Dis. 2016;62(9):1172-1177.
  28. World Health Organization. What’s The 2+1+1? Event-Driven Oral Pre-Exposure Prophylaxis To Prevent HIV For Men Who Have Sex With Men: Update To Who’s Recommendation On Oral Prep. Technical Brief, July 2019. Accessed March 22, 2021.
  29. Molina JM, Capitant C, Spire B, et al; ANRS IPERGAY Study Group. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237-2246.